Matthew L. Kaplan is Director of Nuvectis Pharma, Inc.. Currently has a direct ownership of 83,760 shares of NVCT, which is worth approximately $424,663. The most recent transaction as insider was on Jun 13, 2024, when has been sold 30,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 83.8K
0% 3M change
55.8% 12M change
Total Value Held $424,663

Matthew L. Kaplan Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 13 2024
BUY
Grant, award, or other acquisition
-
30,000 Added 26.37%
83,760 Common Stock
Jun 16 2023
BUY
Grant, award, or other acquisition
-
18,000 Added 25.08%
53,760 Common Stock
May 12 2022
BUY
Open market or private purchase
$50,160 $16.72 p/Share
3,000 Added 7.74%
35,760 Common Stock
MLK

Matthew L. Kaplan

Director
Fort Lee, NJ

Track Institutional and Insider Activities on NVCT

Follow Nuvectis Pharma, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NVCT shares.

Notify only if

Insider Trading

Get notified when an Nuvectis Pharma, Inc. insider buys or sells NVCT shares.

Notify only if

News

Receive news related to Nuvectis Pharma, Inc.

Track Activities on NVCT